脂必泰联合低剂量阿托伐他汀钙治疗高龄高脂血症患者的临床效果

Clinical effect of Zibitai combined with low-dose Atorvastatin Calcium in the treatment of elderly patients with hyperlipidemia

目的 探讨应用脂必泰联合阿托伐他汀钙治疗高龄高脂血症疾病的治疗效果。方法 选择2019年1月至2021年1月在广西国际壮医医院就诊的高龄高脂血症患者120例,采用随机数字表法将其分为对照组60例(阿托伐他汀钙20 mg,1次/d)和观察组60例(脂必泰240 mg,2次/d+阿托伐他汀钙10 mg,1次/d),治疗12周。观察两组患者血脂、肝肾功能、肌酸激酶(CK)和空腹血糖(FPG)的变化,记录不良反应发生情况。结果 治疗后,两组高密度脂蛋白胆固醇(HDL-C)与治疗前比较,差异无统计学意义(P> 0.05),总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG)水平较治疗前降低,差异有统计学意义(P <0.05);治疗后两组TC、LDL-C、HDL-C和TG比较,差异无统计学意义(P> 0.05)。两组治疗后FPG、肌酐水平、CK、ALT水平与治疗前比较及组间比较,差异均无统计学意义(P> 0.05)。两组不良反应发生率比较,差异无统计学意义(P> 0.05)。结论 高脂血症高龄患者使用脂必泰联合低剂量阿托伐他汀钙治疗的效果确切且安全性较好。

Objective To investigate the efficacy of Zibitai combined with Atorvastatin Calcium in elderly patients with hyperlipidemia. Methods From January 2019 to January 2021, 120 elderly patients with hyperlipidemia in Guangxi International Zhuang Medical Hospital were divided into control group(60 cases, Atorvastatin Calcium 20 mg, once a day)and study group(60 cases, 240 mg, twice a day+Atorvastatin Calcium 10 mg, once a day) by random number table method, all treated for 12 weeks. The changes in blood lipid, liver and kidney function, creatine kinase(CK) and fasting plasma glucose(FPG) were deterimined, and adverse events were recorded in both groups. Results After treatment,there was no statistically significant difference in high density lipoprotein-cholesterol(HDL-C) of the two groups compared with before treatment(P > 0.05), while the levels of total cholesterol(TC), low density lipoprotein-cholesterol(LDL-C) and triglyceride(TG) were lower than those before treatment, the differences were statistically significant(P <0.05). There were no significant differences in TC, LDL-C, HDL-C, and TG between the two groups after treatment(P >0.05). There were no significant differences in the levels of FPG, creatinine, CK, and ALT between the two groups after treatment compared with those before treatment and between the groups(P > 0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P > 0.05). Conclusion The efficacy and safety of Zibitai combined with low-dose Atorvastatin Calcium in the treatment of elderly patients with hyperlipidemia are good.